Compare CLOV & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLOV | AGIO |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2020 | 2013 |
| Metric | CLOV | AGIO |
|---|---|---|
| Price | $4.24 | $33.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.90 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 3.4M | 785.4K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,924,308,000.00 | $43,011,000.00 |
| Revenue This Year | $52.59 | $76.75 |
| Revenue Next Year | $15.37 | $170.73 |
| P/E Ratio | $42.55 | ★ N/A |
| Revenue Growth | ★ 40.34 | N/A |
| 52 Week Low | $1.58 | $22.24 |
| 52 Week High | $5.59 | $46.00 |
| Indicator | CLOV | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 42.59 |
| Support Level | $4.09 | $32.54 |
| Resistance Level | $4.23 | $36.04 |
| Average True Range (ATR) | 0.13 | 1.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 52.24 | 9.87 |
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.